Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Deckert

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
EMBO Molecular Medicine|December 27, 2021
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanomaIlona Berestjuk, Margaux Lecacheur, Alexandrine Carminati, et al.
The EMBO Journal|July 11, 2009
The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in miceSandrine Marchetti, Parvati Gamas, Nathalie Belhacène, et al.
Journal of Molecular Cell Biology|April 3, 2012
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressivenessAlexandre Puissant, Maeva Dufies, Nina Fenouille, et al.
Cancer Research|March 18, 2020
A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant MelanomaChristophe A Girard, Margaux Lecacheur, Rania Ben Jouira, et al.
Nature Communications|May 1, 2015
Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasisMélanie Tichet, Virginie Prod'Homme, Nina Fenouille, et al.
EMBO Molecular Medicine|February 14, 2022
Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanomaSerena Diazzi, Alberto Baeri, Julien Fassy, et al.
The Journal of Experimental Medicine|July 27, 2016
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic miceMohamed-Amine Hamouda, Arnaud Jacquel, Guillaume Robert, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
EMBO Molecular Medicine|December 27, 2021
Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix-mediated tumor cell adaptation and tolerance to BRAF-targeted therapy in melanomaIlona Berestjuk, Margaux Lecacheur, Alexandrine Carminati, et al.
The EMBO Journal|July 11, 2009
The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in miceSandrine Marchetti, Parvati Gamas, Nathalie Belhacène, et al.
Journal of Molecular Cell Biology|April 3, 2012
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressivenessAlexandre Puissant, Maeva Dufies, Nina Fenouille, et al.
Cancer Research|March 18, 2020
A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant MelanomaChristophe A Girard, Margaux Lecacheur, Rania Ben Jouira, et al.
Nature Communications|May 1, 2015
Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasisMélanie Tichet, Virginie Prod'Homme, Nina Fenouille, et al.
EMBO Molecular Medicine|February 14, 2022
Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanomaSerena Diazzi, Alberto Baeri, Julien Fassy, et al.
The Journal of Experimental Medicine|July 27, 2016
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic miceMohamed-Amine Hamouda, Arnaud Jacquel, Guillaume Robert, et al.
Pageof 6